CTOs on the Move

RxAdvance

www.rxadvance.com

 
RxAdvance, a national full service PBM, leverages the disruptive Collaborative PBM Cloud™ to manage standard and specialty drug benefits with unmatched regulatory compliance and transparency. In addition, RxAdvance is willing to share global pharmacy risk, avoidable drug-impacted medical risk, and bundled episode specialty pharmacy risk, standing shoulder-to-shoulder with plan sponsors as a true accountable partner. This risk model has never been offered by any other PBM.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.rxadvance.com
  • 2 Park Central Drive
    Southborough, MA USA 01772
  • Phone: 508.804.6900

Executives

Name Title Contact Details
Bijendra Malik
Chief Information Security Officer Profile

Similar Companies

Assistek

Assistek is a Scottsdale, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Shire plc

Shire plc is a Radford, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sanovia

Sanovia s corporate vision is to deliver state-of-the-art products and services which allow its customers to take advantage of advanced technology to improve communications, improve resource utilization through automated workflow processes, advance the quality and appropriateness of care through the integrated use of automated best-practice pharmaceutical clinical guidelines, and control costs.

KESIN PHARMA

Kesin Pharma is a specialty pharmaceutical company that offers a variety of products, including unit dose drug repackaging for liquid medications and creams/ointments.

Edgewise Therapeutics

Edgewise Therapeutics is a biotechnology company harnessing proven expertise and understanding of skeletal muscle physiology to develop novel, transformative therapies for serious muscle diseases. Based in Boulder, Colorado, we have built a state-of-the-art muscle research facility to capitalize on new insights into the nature and consequences of muscle adaptation and injury with disease. Edgewise recently closed it`s Series B financing round which will support the advancement of Edgewise Therapeutic`s lead product candidate into clinical development for Duchenne and Becker Muscular Dystrophy (DMD and BMD) as well as expansion of the company`s pipeline. The company`s leadership team has founded multiple biotechnology startups, several of which have gone on to become publicly-traded companies and brings to bear a depth of experience in drug discovery, development and commercialization.